Genetic Evidence and Integration of Various Data Sources for Classifying Uncertain Variants Into a Single Model

被引:144
作者
Goldgar, David E. [1 ]
Easton, Douglas E. [2 ]
Byrnes, Graham B. [3 ]
Spurdle, Amanda B. [4 ]
Iversen, Edwin S. [5 ]
Greenblatt, Marc S. [6 ,7 ]
机构
[1] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT 84132 USA
[2] Univ Cambridge, Strangeways Res Labs, Genet Epidemiol Unit, Cambridge, England
[3] Int Agcy Res Canc, Epidemiol Methods & Support Grp, F-69372 Lyon, France
[4] Queensland Inst Med Res, Mol Canc Epidemiol Lab, Brisbane, Qld 4006, Australia
[5] Duke Univ, Dept Stat Sci, Durham, NC USA
[6] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA
[7] Univ Vermont, Coll Med, Vermont Canc Ctr, Burlington, VT 05405 USA
基金
美国国家卫生研究院;
关键词
likelihood models; unclassified variants; integrated model; classification;
D O I
10.1002/humu.20897
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Genetic testing often results in the finding of a variant whose clinical significance is unknown. A number of different approaches have been employed in the attempt to classify such variants. For some variants, case-control, segregation, family history, or other statistical studies can provide strong evidence of direct association with cancer risk. For most variants, other evidence is available that relates to properties of the protein or gene sequence. In this work we propose a Bayesian method for assessing the likelihood that a variant is pathogenic. We discuss the assessment of prior probability, and how to combine the various sources of data into a statistically valid integrated assessment with a posterior probability of pathogenicity. In particular, we propose the use of a two-component mixture model to integrate these various sources of data and to estimate the parameters related to sensitivity and specificity of specific kinds of evidence. Further, we discuss some of the issues involved in this process and the assumptions that underpin many of the methods used in the evaluation process. Hum Mutat 29(11), 1265-1272, 2008. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:1265 / 1272
页数:8
相关论文
共 37 条
[1]   Two PMS2 mutations in a Turcot syndrome family with small bowel cancers [J].
Agostini, M ;
Tibiletti, MG ;
Lucci-Cordisco, E ;
Chiaravalli, A ;
Morreau, H ;
Furlan, D ;
Boccuto, L ;
Pucciarelli, S ;
Capella, C ;
Boiocchi, M ;
Viel, A .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (08) :1886-1891
[2]   The BOADICEA model of genetic susceptibility to breast and ovarian cancer [J].
Antoniou, AC ;
Pharoah, PPD ;
Smith, P ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1580-1590
[3]   Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing [J].
Auclair, J ;
Buisine, MP ;
Navarro, C ;
Ruano, E ;
Montmain, G ;
Desseigne, F ;
Saurin, JC ;
Lasset, C ;
Bonadona, V ;
Giraud, S ;
Puisieux, A ;
Wang, Q .
HUMAN MUTATION, 2006, 27 (02) :145-154
[4]   Sequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphisms [J].
Balasubramanian, S ;
Xia, Y ;
Freinkman, E ;
Gerstein, M .
NUCLEIC ACIDS RESEARCH, 2005, 33 (05) :1710-1721
[5]   Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer [J].
Barnetson, Rebecca A. ;
Cartwright, Nicola ;
van Vliet, Annelot ;
Haq, Naila ;
Drew, Kate ;
Farrington, Susan ;
Williams, Nicola ;
Warner, Jon ;
Campbell, Harry ;
Porteous, Mary E. ;
Dunlop, Malcolm G. .
HUMAN MUTATION, 2008, 29 (03) :367-374
[6]   Likelihood ratios to assess genetic evidence for clinical significance of uncertain variants: Hereditary hemorrhagic telangiectasia as a model [J].
Bayrak-Toydemir, Pinar ;
McDonald, Jamie ;
Mao, Rong ;
Phansalkar, Amit ;
Gedge, Friederike ;
Robles, Jorge ;
Goldgar, David ;
Lyon, Elaine .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2008, 85 (01) :45-49
[7]   BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [J].
Berry, DA ;
Iversen, ES ;
Gudbjartsson, DF ;
Hiller, EH ;
Garber, JE ;
Peshkin, BN ;
Lerman, C ;
Watson, P ;
Lynch, HT ;
Hilsenbeck, SG ;
Rubinstein, WS ;
Hughes, KS ;
Parmigiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2701-2712
[8]   Interpreting missense variants:: Comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR) [J].
Chan, Philip A. ;
Duraisamy, Sekhar ;
Miller, Peter J. ;
Newell, Joan A. ;
McBride, Carole ;
Bond, Jeffrey P. ;
Raevaara, Tiina ;
Ollila, Saara ;
Nystrom, Minna ;
Grimm, Andrew J. ;
Christodoulou, John ;
Oetting, William S. ;
Greenblatt, Marc S. .
HUMAN MUTATION, 2007, 28 (07) :683-693
[9]   Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR) [J].
Chao, Elizabeth C. ;
Velasquez, Jonathan L. ;
Witherspoon, Mavee S. L. ;
Rozek, Laura S. ;
Peel, David ;
Ng, Pauline ;
Gruber, Stephen B. ;
Watson, Patrice ;
Rennert, Gad ;
Anton-Culver, Hoda ;
Lynch, Henry ;
Lipkin, Steven M. .
HUMAN MUTATION, 2008, 29 (06) :852-860
[10]   Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance [J].
Chenevix-Trench, G ;
Healey, S ;
Lakhani, S ;
Waring, P ;
Cummings, M ;
Brinkworth, R ;
Deffenbaugh, AM ;
Burbidge, LA ;
Pruss, D ;
Judkins, T ;
Scholl, T ;
Bekessy, A ;
Marsh, A ;
Lovelock, P ;
Wong, M ;
Tesoriero, A ;
Renard, H ;
Southey, M ;
Hopper, JL ;
Yannoukakos, K ;
Brown, M ;
Easton, D ;
Tavtigian, SV ;
Goldgars, D ;
Spurdle, AB .
CANCER RESEARCH, 2006, 66 (04) :2019-2027